Center-Authored Papers

Filters: Keyword is Neoplasm, Residual  [Clear All Filters]
A
Appelbaum FR.  2008.  Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML).. Best practice & research. Clinical haematology. 21(1):85-92. Abstract
B
Bensinger WI.  2009.  Role of autologous and allogeneic stem cell transplantation in myeloma.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 23(3):442-8. Abstract
Bishop MR, Alyea EP, Cairo MS, Falkenburg FJH, June CH, Kröger N, Little RF, Miller JS, Pavletic SZ, Porter DL et al..  2011.  National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(4):443-54. Abstract
F
Fang M, Storer BE, Wood B, Gyurkocza B, Sandmaier BM, Appelbaum FR.  2012.  Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation.. Cancer. 118(9):2411-2419. Abstract
G
Gopal AK, Pagel JM, Hedin N, Press OW.  2004.  Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism.. Blood. 103(9):3516-20. Abstract
Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B et al..  2008.  Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(5):814-9. Abstract
K
Kuball J, de Boer K, Wagner E, Wattad M, Antunes E, Weeratna RD, Vicari AP, Lotz C, van Dorp S, Hol S et al..  2011.  Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.. Cancer immunology, immunotherapy : CII. 60(2):161-71. Abstract
M
Milano F, Appelbaum FR, Delaney C.  2016.  Cord-Blood Transplantation in Patients with Minimal Residual Disease-Reply to Gupta, Hourigan, et al.. The New England journal of medicine. 375(22):2204-2205.
Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, Witherspoon R, Mielcarek M, Deeg HJ, Sorror M et al..  2016.  Cord-Blood Transplantation in Patients with Minimal Residual Disease.. The New England journal of medicine. 375(10):944-53. Abstract
P
Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur SD, Orgun N, Kenoyer AL, Frayo S, Axtman A, Bäck T et al..  2010.  Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.. Blood. 116(20):4231-9. Abstract
R
Radich JP.  2009.  How I monitor residual disease in chronic myeloid leukemia.. Blood. 114(16):3376-81. Abstract
Rajendran JG, Gopal AK, Fisher DR, Durack LD, Gooley TA, Press OW.  2008.  Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 49(5):837-44. Abstract
Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman PW, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X et al..  2010.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.. The lancet oncology. 11(6):543-52. Abstract
S
Spalding AC, Hawkins DS, Donaldson SS, Anderson JR, Lyden E, Laurie F, Wolden SL, Arndt CAS, Michalski JM.  2013.  The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803.. International journal of radiation oncology, biology, physics. 87(3):512-6. Abstract
W
Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, Estey EH, Salter AI, Lansverk E, Chien JW et al..  2011.  Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(9):1190-7. Abstract